Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 869 results found since Jan 2013.
Aspirin in the Modern Era of Cardiovascular Disease Prevention
Methodist Debakey Cardiovasc J. 2021 Sep 24;17(4):36-47. doi: 10.14797/mdcvj.293. eCollection 2021.ABSTRACTAspirin's antithrombotic effects have a long-established place in the prevention of cardiovascular disease (CVD), and its traditional use as a core therapy for secondary prevention of CVD is well recognized. However, with the advent of newer antiplatelet agents and an increasing understanding of aspirin's bleeding risks, its role across the full spectrum of modern CVD prevention has become less certain. As a consequence, recent trials have begun investigating aspirin-free strategies in secondary prevention. For exampl...
Source: Methodist DeBakey Cardiovascular Journal - November 26, 2021 Category: Cardiology Authors: Ella Murphy James M G Curneen John W McEvoy Source Type: research
CHA2 DS2 -VASc score as a predictor for contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention
ConclusionCHA2DS2-VASc score is a simple risk score for bedside, preprocedure CIN risk stratification among ACS patients who underwent primary PCI.
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants
Rev Cardiovasc Med. 2021 Sep 24;22(3):635-648. doi: 10.31083/j.rcm2203074.ABSTRACTAtrial fibrillation (AF) represents the most prevalent supraventricular arrhythmia in adults population and up to 15% of AF patients undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD) during their life. While oral anticoagulants (OACs) exert a protective effect in the setting of stroke prevention and systemic embolization in AF patients, patients undergoing PCI are recommended to receive dual antiplatelet therapy (DAPT) to reduce the risk of cardiovascular death, recurrent myocardial infarction and stent thromb...
Source: Reviews in Cardiovascular Medicine - September 26, 2021 Category: Cardiology Authors: Pier Paolo Bocchino Filippo Angelini Elisabetta Toso Source Type: research
